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ABSTRACT
Increasing attention is focused on the down-regulation
of miRNAs in cancer process. Nuclear receptor sub-
family 2 (NR2F2, also known as COUP-TFII) is involved
in the development of many types of cancers, but its role
in gastric cancer remains elusive. In this experiment,
oncomine and Kaplan-meier database revealed that
NR2F2 was up-regulated in gastric cancer and that the
high NR2F2 expression contributed to poor survival.
MicroRNA-27b was targeted and down-regulated by
NR2F2 in human gastric cancer tissues and cells. The
ectopic expression of miR-27b inhibited gastric cancer
cell proliferation and tumor growth in vitro and in vivo.
Assays suggested that the overexpression of miR-27b
could promote MGC-803 cells’ migration and invasion
and retard their metastasis to the liver. In addition,
down-regulation of miR-27b enhanced GES-1 cells’
proliferation and metastasis in vitro. These ﬁndings
reveal that miR-27b is a tumor suppressor in gastric
cancer and a biomarker for improving patients’ survival.
KEYWORDS miR-27b, NR2F2, gastric cancer, tumor
metastasis
INTRODUCTION
Gastric cancer (GC), the second leading cause of cancer-
induced death, has a high incidence in countries like China
or Japan (Kang et al., 2014; Yan et al., 2015). Various innate
and acquired factors, including H. pylori infection, genetic,
epigenetic and molecular alterations, are involved in gastric
tumorigenesis via their impact on genetic expression and
signaling pathways (Milne et al., 2009). However, the
mechanism of GC oncogenesis remains unknown. Nuclear
receptor subfamily 2 (NR2F2, group F, member 2, also
known as COUP-TFII or ARP1) is a key molecule in mes-
enchymal-epithelial interaction during organogenesis (Tsai
and Tsai, 1997). Meanwhile, Kieback et al. ﬁnd that NR2F2 is
expressed in tumor cell lines of human endometrial (Kieback
et al., 1996), pancreatic (Qin et al., 2010), colorectal (Shin
et al., 2009), and breast cancers (Prahalad et al., 2010). The
expression of NR2F2 in terminally differentiated epithelial
cells functions in mesenchymal-endothelial interactions,
angiogenesis, tumor growth and metastasis by inhibiting
TGF-β-induced growth (Qin et al., 2013).
MicroRNAs (miRs), as small single-stranded noncoding
RNAs, are key post-transcriptional negative regulators that
completely or partially bind to complementary sites in the 3′-
untranslated-region (3′UTR) of target mRNAs. Recent stud-
ies show that miRNAs can regulate tumor growth,
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metastasis and progression (Ma et al., 2007; Ruan et al.,
2009; Aleckovic and Kang, 2015). A single miRNA can
downregulate the expression of multiple target genes and
thereby inhibit tumor metastasis. Therefore, miRNAs can be
targeted to modulate the invasion-metastasis cascade (Lin
et al., 2015). MiR-27b is a strain of intronic miRNA that
regulates chondrosarcoma (Huang et al., 2016), cervical
carcinogenesis (Yao et al., 2016) and neuroblastom (Lee
et al., 2012).
Interestingly, a recent report demonstrates that the lower
level of miR-27b expression correlates with gastric cancer
proliferation (Tao et al., 2015). However, little is known about
the function of miR-27b in gastric cancer metastasis. In our
study, miR-27b was downregulated in gastric cancer tissues,
with an inverse correlation with lymph node metastasis.
Meanwhile, the miR-27b overexpression inhibited the prolif-
eration and invasion of gastric cancer cells in vitro and
suppresses tumor growth and liver metastasis of gastric
cancer cells in vivo. Conversely, miR-27b inhibitors signiﬁ-
cantly enhanced the proliferation and invasion of gastric
cancer cell in vitro. Our study concludes that miR-27b plays
a suppressive role in gastric cancer metastasis.
RESULTS
Survival time shortened by high NR2F2 expression
in gastric cancer
The expression of NR2F2 was measured in gastric cancer
patients by oncomine database. NR2F2 was signiﬁcantly up-
regulated in gastric cancer tissues compared with normal
tissues (Fig. 1A). Q-RT found that NR2F2 expression was
signiﬁcantly higher in gastric cancer tissues than in normal
tissues (Fig. 1B). Analysis of immunohistochemical staining
and Western blot also support this result (Fig. S1). We
subsequently used oncomine database to determine the
correlation between the NR2F2 level and the survival time.
Although the survival rate had no signiﬁcant difference
(Fig. 1C), the high level of NR2F2 brought a shorter survival
time than the low level of NR2F2 did. Then we used Kaplan-
meier piotter database to determine the inﬂuence of NR2F2
on the survival of gastric cancer patients. The results told
that the high level of NR2F2 caused poor clinical survival of
patients. (Fig. 1D). All results conclude that the up-regulated
NR2F2 level in gastric tissues is negatively correlated with
patients’ survival.
Suppressive role of miR-27b in gastric cancer
Enough evidence demonstrates that miR-27b, like miRNA,
can suppress the proliferation of gastric cancer by targeting
ROR1 (Tao et al., 2015). Currently, the function of miR-27b in
gastric cancer metastasis remains unclear. To determine its
exact function, Q-RTwas performed to detect the expression
level of miR-27b in gastric cancer tissues and cell lines. As is
shown in Fig. 2A, miR-27b expression was signiﬁcantly
decreased in gastric cancer samples compared to matched
normal tissues. Of all the patients, 89.47% (17/19) had a
lower expression of miR-27b in tumor tissues than that in the
adjacent mucosa (Fig. 2B). We further tested the correlation
between the level of miR-27b expression and the metastasis
of gastric cancer, ﬁnding that both were negatively associ-
ated (Fig. 2C). We also observed that miR-27b expression
was lower in gastric cancer cell lines MGC-803 than in GES-
1 cells (human immortalized gastric epithelial cell line)
(Fig. 2D). These results prove that the miR-27b level is
down-regulated in gastric cancer tissues and gastric cancer
cell lines, and is negatively correlated with the metastasis of
gastric cancer.
Cell proliferation, migration and invasion suppressed
by miR-27b in gastric cancer
To evaluate the biological function of miR-27b in gastric
cancer, the cell line MGC-803 with low expression of
endogenous miR-27b was stably transfected with miR-27b
by lentiviral infection (Fig. S2A). MTTassays showed that the
ectopic overexpression of miR-27b suppressed the prolifer-
ation of MGC-803 cells (Fig. 3A). Moreover, soft agar for-
mation assays revealed that overexpression miR-27b could
inhibit the expanding of MGC-803 cellular colonies (Fig. 3B).
The effects of miR-27b on the migration and invasion of
gastric cancer cells were further examined by Transwell
assays. The ectopic overexpression of miR-27b in MGC-803
cells dramatically inhibited cell migration (Fig. 3C). Also, we
used a Matrigel transmembrane invasion assay to study the
invasive properties of MGC-803 cells. Overexpression of
miR-27b reduced the invasiveness of gastric cancer cells.
Consistent with these phenotypes, then we detected that
mRNA levels of MMP2, MMP9, Cyclin D1, c-Myc and the
protein levels of c-Myc and Cyclin D1 were downregulated
with overexpressed miR-27b (Fig. 3D and 3E). These results
suggest that miR-27b can suppress the proliferation,
migration and invasion of gastric cancer cells and inhibit the
growth and metastasis of gastric cancer.
Proliferation, invasion and metastasis of GES-1 cells
promoted by the knockdown of miR-27b Given that the
overexpression of miR-27b inhibited the proliferation,
migration and invasion of gastric cancer cells, we performed
loss-of-function experiments to verify the function of miR-27b
in GES-1 cells. First, we used miR-27b inhibitor to knock
down endogenous miR-27b in GES-1 cells. Q-RT detected
that the level of miR-27b was signiﬁcantly down-regulated by
about 70% after the transfection with miR-27b inhibitor
(Supplementary Figure 2B). Next, we explored whether miR-
27b inhibitor could augment the proliferation of GES-1 cells.
Notably, the miR-27b inhibitor dramatically increased the
ability of GES-1 cells in colony formation in a serial passage
MTT assay and a soft agar assay (Fig. 4A and 4B). Similar
data were obtained by Transwell analysis. The miR-27b
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increased the migration and invasion of GES-1 cells
(Fig. 4C) and the mRNA expression of MMP2, MMP9 and
CyclinD1, c-Myc. The protein levels of Cyclin D1 and c-Myc
were dramatically upregulated (Fig. 4D and 4E).
Gastric tumor growth and metastasis inhibited by miR-
27b in vivo
To determine whether miR-27b can inhibit the growth and
metastasis of gastric cancer cells in vivo, we generated
luciferase-labeled MGC-803/miR-27b cells and their control
counterparts, and then injected them into the orthotopic sites
or spleens of nude mice. Compared with the mice injected
with MGC-803/ctrl cells, the mice injected with a combination
of MGC-803 with miR-27b cells displayed signiﬁcantly
smaller and lighter tumors four weeks later (Fig. 5A). More-
over, bioluminescence imaging of mice with a 4-week
injection of MGC-803/miR-27b or MGC-803/ctrl cells showed
that the metastasis of MGC-803 liver cells was signiﬁcantly
impaired by the ectopic overexpression of miR-27b (Fig. 5B).
NR2F2 directly targeted by miR-27b
To reveal the underlying mechanism in which miR-27b inhi-
bits the growth and metastasis of gastric cancer cells, we
used silico algorithms Targetscan, miRanda and some other
methods to predict the target genes of miR-27b. We found
NR2F2 with greater than 30% decreased expression upon
ectopic miR-27b overexpression in MGC-803 cells and miR-
27b inhibitor increased the level of NR2F2 expression
(Fig. 6A). We constructed luciferase reporter vectors con-
taining wide-type or mutant 3′UTRs of NR2F2 (Fig.6B).
Luciferase activity assays revealed that miR-27b sup-
pressed the expression of luciferase containing 3′UTRs of
NR2F2, compared with controls on 293T cells and MGC-803
cells (Fig. 6C). We found possible binding sites of miR-27b in
3′UTRs of NR2F2, and obliterated these sites by Quick-
Change PCR (Zheng et al., 2004). As is shown in Fig. 6D,
the mutation of binding sites in 3′UTRs of NR2F2 reversed
the downregulation on luciferase activity induced by miR-
27b, and abrogated the suppressing effect of miR-27b
Normal tissue 
High NR2F2 expression = 208
Low NR2F2 expression = 423
P = 0.00018
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Figure 1. NR2F2 is up-regulated in human gastric cancer tissues and High NR2F2 level have poor clinical outcome. (A) The
expression of NR2F2 in human gastric cancer tissue samples from oncomine database. (B) qRT-PCR analysis of NR2F2 expression
in human gastric cancer tissue samples and their matched normal gastric tissues from 19 gastric cancer patients. (C) The High
expression of NR2F2 in human gastric cancer tissues have trends to poor clinical outcome by oncomine database. (D) The High
expression of NR2F2 in human gastric cancer tissues have poor clinical outcome by Kalpan meier-Poitter. Scale bars, 100 μm. *P <
0.05, **P < 0.01, ***P < 0.001.
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overexpression. These results indicate that NR2F2 is the
direct target of miR-27b in gastric cancer cells.
DISCUSSION
Tumorigenesis and metastasis are complex neoplastic pro-
cesses triggered by a body of transcriptive factors. The
abnormal expression of miRNA is involved in tumor prolif-
eration and invasion by inhibiting their target genes (Zhang
and Ma, 2012; Zhang et al., 2014b). Therefore, the identiﬁ-
cation of speciﬁc miRNAs and their targets engaged in
tumorigenesis and metastasis can provide clues for diag-
nosing, treating and preventing the cancer. The mechanism
that miR-27b participates in gastric cancer proliferation is
clear (Tao et al., 2015), but the mechanism in metastasis
remains elusive.. In this report, we demonstrated that miR-
27b took part in the proliferation and metastasis of gastric
cancer. MiR-27b exhibited a decreased expression level in
gastric cancer tissues. Moreover, in patients with gastric
cancer, a correlation was clariﬁed between lowered miR-27b
expression and increased lymphatic metastasis. MiR-27b
inhibited proliferation, migration, and invasion of gastric
cancer cells in vitro and suppressed tumor growth and its
metastasis to the liver in vivo. In conclusion, miR-27b is a
tumor-suppressing gene in gastric cancer metastasis.
Nuclear receptor subfamily 2 (NR2F2,as known as COUP-
TFII) is found in many cancers, including breast cancer
(Zhang et al., 2014a), ovarian cancer (Hawkins et al., 2013)
and colorectal cancer (Zhou et al., 2016) . Oncomine data-
base and Kaplan meier-piotter deﬁned that NR2F2 was an
oncogene in gastric cancer. With Targetscan, miRanda, mir-
walk, and Pictar databases, we found highly conserved miR-
27b binding sites in the 3′UTRs of NR2F2. Moreover, the
miR-27b level was inversely associated with the expression
of NR2F2 in gastric cancer tissues, indicating that miR-27b
can inhibit gastric cancerous proliferation and metastasis, at
least in part, by downregulating the levels of NR2F2.
In all, this experiment provides evidence that miR-27b is a
suppressor gene in gastric cancer proliferation and metas-
tasis. MiR-27b can inhibit the proliferation and metastasis of
gastric cancer cells by suppressing NR2F2. Furthermore,
this experiment provides a potential diagnostic and prog-
nostic marker for gastric cancer metastasis to liver.



































































































































***  *** 
Figure 2. miR-27b is downregulated in human gastric cancer tissues and metastatic gastric cancer cell lines. (A) The
expression of miR-27b in human gastric cancer tissue samples and matched normal tissues from 19 gastric cancer patients was
analyzed by real-time PCR. (B) miR-27b were expressed as log2 fold change to show the relative expression in every paired sample.
(C) Correlation between the lymph node metastasis status and the level of miR-27b in gastric cancers (n = 19). (D) The expression of
miR-27b in gastric cancer cell lines with different metastatic potentials was analyzed by real-time PCR. Scale bars, 100 μm. *P < 0.05,
**P < 0.01, ***P < 0.001.
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Cell lines and clinical samples
GES-1, MGC-803, BGC-823, SGC-7901 and 293T cells were saved
in our lab (from Institute of Health Sciences, Shanghai Institute for
Biological Sciences, Shanghai). 293T cells were cultured in DMEM
supplemented with 10% fetal bovine serum. GES-1, MGC-803,
BGC-823 and SGC-7901 cells were maintained in RPMI 1640 media
supplemented with 10% fetal bovine serum.
Nineteen paired gastric cancer and normal adjacent tissues were
collected from The Afﬁliated Drum Tower Hospital of Medical School
of Nanjing University, Jiangsu, China. All patients were diagnosed
pathologically according to the criteria of the American Joint Com-


































































































































*** ***  
MGC-803/Ctrl
MGC-803/miR-27b
Figure 3. miR-27b inhibits gastric cancer cell growth, migration, and invasion in vitro. (A) The effect on cell proliferation of miR-
27b overexpression in MGC-803 cells was determined by the MTT assay. (B) Representative images show the colony formation of
MGC-803/miR-27b and their control cells (left panel). Average colonies in each well for each group were counted from three
independent experiments (right panel). (C) The effects of miR-27b overexpression in MGC-803 cells on cell migration and invasion
were analyzed by Transwell migration and Matrigel-coated Transwell invasion analyses. (D) Q-RT analysis of proliferation and
metastasis genes. (E) Western blot analysis of proliferation and metastasis genes. *P < 0.05, **P < 0.01, ***P < 0.001.
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Specimens were obtained with informed consent and the study was
performed in accordance with the approved guidelines by the
Medical Ethics Committee of the Afﬁliated Drum Tower Hospital of
Nanjing University (Nanjing, China).
Plasmid construction and generation of stable cell lines
An hsa-miR-27b-containing ﬂank region was ampliﬁed from human
genomic DNA and inserted into pCDH-CMV-EF1-GFP+puro (Sys-
































































































































































Figure 4. miR-27b inhibitor promotes gastric cancer cell growth, migration, and invasion in vitro. (A) The effect on cell
proliferation of miR-27b inhibitor in GES-1 cells was determined by the MTT assay. (B) Representative images show the colony
formation of GES-1/miR-27b inhibitor and their control cells (left panel). Average colonies in each well for each group were counted
from three independent experiments (right panel). (C) The effects of miR-27b inhibitor in GES-1 cells on cell migration and invasion
were analyzed by Transwell migration and Matrigel-coated Transwell invasion analyses. (D) Q-RT analysis proliferation and
metastasis genes. (E) Western blot analysis of proliferation and metastasis genes. *P < 0.05, **P < 0.01, ***P < 0.001.
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cloned into the pMIR-REPORT miRNA Expression Reporter Vector
(Ambion). To generate a miR-27b-expressing stable cell line, a
lentivirus-mediated packaging system containing four plasmids,
pCDH-miR-27b or control plasmid, pMDL, REV, and VSVG, was
used. To knock down miR-27b in GES-1 cells, miR-27b inhibitor was
used GenePharma Colone Primer sequences were as follows: miR-
27b Fw-GC TCTAGA TTGCCAGGGATTACCACGCAA; Rv-CG
GGATCC CTAGCATTCCCAGCAGGAGACAG NR2F2; 3′UTR Fw-
CG ACGCGT AAGAAGGGGGAGTGAAACAGAG; Rv-CCC
AAGCTT AGCAAGTTGTTCTGACCGACA.
Western blot
Western blot was performed as described previously (Lin et al.,
2015). Cell lysates were separated on SDS-polyacrylamide gels and
immunoblot analysis was performed with primary antibodies against
NR2F2 (Abcam, Cambridge, MA, USA), β-actin (Millipore, Billerica,
MA, USA), c-Myc (Cell Signaling Technology, Danvers, MA) and
Cyclin D1 (Sigma-Aldrich).
Cell growth assay
For the MTT assay, 1000 cells were seeded and transfected in a
96-well plate. After transfection for 1, 2, 3, 4 days, and the absor-
bance at 490 nm was measured. For soft agar assay, 3000 cells
were seeded and transfected in a 6-well plate. After transfection for
14 days, and the size and number of soft agar colonies were mea-
sured. Experiments were repeated three times.
Oncomine and TCGA database analysis
The Oncomine, TCGA and Kalpan meier-plotter database was
searched for NR2F2 gene. The data sets containing expression data
for NR2F2 were ﬁltered to display up-regulation in gastric cancer
versus normal tissue with P < 0.05 and have poor clinical outcome.
Real-time quantitative PCR
Total RNAwas extracted from the cultured cells or frozen tissues using







































































Figure 5. miR-27b suppresses tumor growth and liver metastasis of gastric cancer cells in vivo. (A) Representative images of
primary tumors in the nude mice orthotopically injected with MGC-803/miR-27b or MGC-803/ctrl cells in the leg (left). Quantiﬁcation of
tumors in each group is shown (right). (B) Representative bioluminescence images of mice injected with MGC-803/miR-27b or MGC-
803/ctrl cells into spleen to show liver metastases (left). Quantiﬁcation of liver metastases was analyzed by bioluminescence
measurement (right). Scale bars, 100 μm. *P < 0.05, **P < 0.01, ***P < 0.001.
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reverse-transcribed by anRT-PCR kit (Invitrogen, Carlsbad, California,
USA) according to the manufacturer’s instructions. Quantitative PCR
was then performed with primers for miR-27b, NR2F2 using SYBR
Green PCR Master Mix (Invitrogen, Carlsbad, California, USA) in a
real-time PCR System (Applied Biosystems, Carlsbad, California,
USA) following a standard quantitative PCR procedure. Primer
sequences used are shown in Table S1.
Relative quantiﬁcation was performed by normalization to the
amount of GAPDH or U6.
Cell motility and invasion assay
Migration and invasion assays were performed as described previ-
ously (Liu et al., 2014). All experiments were performed at least
three times in triplicate.
miRNA reporter luciferase assay
For luciferase reporter assays, 293T cells and MGC-803 cells were
seeded into a 24-well plate and co-transfected with 3′UTR-luciferase
and either miR-27b or control plasmids. Cells were harvested after
two days and assayed using the Dual-Glo Luciferase Assay System
(Promega) to determine the relative luciferase activity. The luciferase
activity was measured by a luciferin enzyme detection assay kit
(Promega) and normalized to Renilla luciferase activity. Each treat-
ment was performed in triplicate in three independent experiments.
Animal studies
All of the experiments using animals were performed in accordance
with a protocol approved by the Animal Care and Use Committee of
Nanjing University. For tumor growth assays, 5 × 106 cells were
subcutaneously injected into the lower back regions of 6-week-old
male nude mice for four weeks (n = 3 per group). For orthotropic
metastasis, 6-week-old male nude mice were anesthetized and their
spleens were exteriorized by laparotomy, and then 5 × 105 cells were
injected into the spleens for four weeks (n = 3 per group). Tumor
growth and hepatic metastases at day 28 were monitored using the
live animal Lumina II system (Xenogen IVIS system).
Statistical analysis
All data were expressed as the mean ± SD. Statistical analysis was
performed with Student’s t-test. A P value less than 0.05 was con-
sidered statistically signiﬁcant.
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Figure 6. NR2F2 are direct targets of miR-27b. (A) The mRNA levels of NR2F2 in MGC-803/miR-27b and MGC-803/ctrl cells were
analyzed by real-time PCR. The mRNA levels of NR2F2 in GES-1/miR-27b inhibitor and GES-1/ctrl cells were further analyzed by
real-time PCR. (B) Constructed luciferase reporter vectors containing wild-type or mutant 3′UTRs of NR2F2. (C) The effects of miR-
27b overexpression on the activity of the 3′UTRs of target genes in 293T cells and MGC-803 cells were analyzed by the dual
luciferase reporter assay. (D) The effects of miR-27b expression on the activity of wild-type and mutant 3′UTRs of NR2F2 were
analyzed by the dual luciferase reporter assay. N.S.: no signiﬁcance, *P < 0.05, **P < 0.01, ***P < 0.001.
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